Improvement of cisplatin-related renal dysfunction by synthetic ghrelin: A prospective randomised phase II trial

Yoshitomo Yanagimoto, Shuji Takiguchi, Yasuhiro Miyazaki, Tomoki Makino, Tsuyoshi Takahashi, Yukinori Kurokawa, Makoto Yamasaki, Hiroshi Miyata, Kiyokazu Nakajima, Hiroshi Hosoda, Kenji Kangawa, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background:Ghrelin, a 28-amino acid peptide predominantly produced by the stomach, exerts powerful renal protective effects by increasing levels of insulin-like growth factor-1 (IGF-1). The aim of this study was to evaluate the effects of ghrelin on the incidence of renal dysfunction in patients receiving cisplatin-based chemotherapy.Methods:Forty patients with oesophageal cancer receiving cisplatin-based chemotherapy were assigned to either the ghrelin group (n=20), which received ghrelin (0.5 μg kg -1 h -1) for 5 days, or a placebo group (n=20). The primary endpoint was serum creatinine. Secondary endpoints were serum cystatin C, chemotherapy-related adverse events, changes in serum ghrelin-related hormone levels, correlation between markers of renal injury and hormone concentrations, and effects on the second cycle of chemotherapy.Results:Blood acyl ghrelin, total ghrelin, and IGF-1 concentrations on day 4 were significantly higher in the ghrelin group. The renal dysfunction, serum creatinine and cystatin C levels, dose reduction, and delay in the initiation of the second cycle of chemotherapy were lower in the ghrelin group than in the control group. Serum creatinine levels were significantly correlated with serum IGF-1 levels.Conclusion:Continuous synthetic ghrelin administration during cisplatin-based chemotherapy attenuated renal dysfunction and harmful effects on subsequent chemotherapy, possibly by increasing IGF-1 levels.

Original languageEnglish
Pages (from-to)1318-1325
Number of pages8
JournalBritish journal of cancer
Volume114
Issue number12
DOIs
Publication statusPublished - Jun 14 2016

Fingerprint

Ghrelin
Cisplatin
Kidney
Drug Therapy
Somatomedins
Serum
Cystatin C
Creatinine
Hormones
Esophageal Neoplasms
Stomach
Placebos
Amino Acids
Control Groups
Peptides

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Yanagimoto, Y., Takiguchi, S., Miyazaki, Y., Makino, T., Takahashi, T., Kurokawa, Y., ... Doki, Y. (2016). Improvement of cisplatin-related renal dysfunction by synthetic ghrelin: A prospective randomised phase II trial. British journal of cancer, 114(12), 1318-1325. https://doi.org/10.1038/bjc.2016.160

Improvement of cisplatin-related renal dysfunction by synthetic ghrelin : A prospective randomised phase II trial. / Yanagimoto, Yoshitomo; Takiguchi, Shuji; Miyazaki, Yasuhiro; Makino, Tomoki; Takahashi, Tsuyoshi; Kurokawa, Yukinori; Yamasaki, Makoto; Miyata, Hiroshi; Nakajima, Kiyokazu; Hosoda, Hiroshi; Kangawa, Kenji; Mori, Masaki; Doki, Yuichiro.

In: British journal of cancer, Vol. 114, No. 12, 14.06.2016, p. 1318-1325.

Research output: Contribution to journalArticle

Yanagimoto, Y, Takiguchi, S, Miyazaki, Y, Makino, T, Takahashi, T, Kurokawa, Y, Yamasaki, M, Miyata, H, Nakajima, K, Hosoda, H, Kangawa, K, Mori, M & Doki, Y 2016, 'Improvement of cisplatin-related renal dysfunction by synthetic ghrelin: A prospective randomised phase II trial', British journal of cancer, vol. 114, no. 12, pp. 1318-1325. https://doi.org/10.1038/bjc.2016.160
Yanagimoto, Yoshitomo ; Takiguchi, Shuji ; Miyazaki, Yasuhiro ; Makino, Tomoki ; Takahashi, Tsuyoshi ; Kurokawa, Yukinori ; Yamasaki, Makoto ; Miyata, Hiroshi ; Nakajima, Kiyokazu ; Hosoda, Hiroshi ; Kangawa, Kenji ; Mori, Masaki ; Doki, Yuichiro. / Improvement of cisplatin-related renal dysfunction by synthetic ghrelin : A prospective randomised phase II trial. In: British journal of cancer. 2016 ; Vol. 114, No. 12. pp. 1318-1325.
@article{2e9739d1e81d45d9b8012dc5c6b3326b,
title = "Improvement of cisplatin-related renal dysfunction by synthetic ghrelin: A prospective randomised phase II trial",
abstract = "Background:Ghrelin, a 28-amino acid peptide predominantly produced by the stomach, exerts powerful renal protective effects by increasing levels of insulin-like growth factor-1 (IGF-1). The aim of this study was to evaluate the effects of ghrelin on the incidence of renal dysfunction in patients receiving cisplatin-based chemotherapy.Methods:Forty patients with oesophageal cancer receiving cisplatin-based chemotherapy were assigned to either the ghrelin group (n=20), which received ghrelin (0.5 μg kg -1 h -1) for 5 days, or a placebo group (n=20). The primary endpoint was serum creatinine. Secondary endpoints were serum cystatin C, chemotherapy-related adverse events, changes in serum ghrelin-related hormone levels, correlation between markers of renal injury and hormone concentrations, and effects on the second cycle of chemotherapy.Results:Blood acyl ghrelin, total ghrelin, and IGF-1 concentrations on day 4 were significantly higher in the ghrelin group. The renal dysfunction, serum creatinine and cystatin C levels, dose reduction, and delay in the initiation of the second cycle of chemotherapy were lower in the ghrelin group than in the control group. Serum creatinine levels were significantly correlated with serum IGF-1 levels.Conclusion:Continuous synthetic ghrelin administration during cisplatin-based chemotherapy attenuated renal dysfunction and harmful effects on subsequent chemotherapy, possibly by increasing IGF-1 levels.",
author = "Yoshitomo Yanagimoto and Shuji Takiguchi and Yasuhiro Miyazaki and Tomoki Makino and Tsuyoshi Takahashi and Yukinori Kurokawa and Makoto Yamasaki and Hiroshi Miyata and Kiyokazu Nakajima and Hiroshi Hosoda and Kenji Kangawa and Masaki Mori and Yuichiro Doki",
year = "2016",
month = "6",
day = "14",
doi = "10.1038/bjc.2016.160",
language = "English",
volume = "114",
pages = "1318--1325",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Improvement of cisplatin-related renal dysfunction by synthetic ghrelin

T2 - A prospective randomised phase II trial

AU - Yanagimoto, Yoshitomo

AU - Takiguchi, Shuji

AU - Miyazaki, Yasuhiro

AU - Makino, Tomoki

AU - Takahashi, Tsuyoshi

AU - Kurokawa, Yukinori

AU - Yamasaki, Makoto

AU - Miyata, Hiroshi

AU - Nakajima, Kiyokazu

AU - Hosoda, Hiroshi

AU - Kangawa, Kenji

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2016/6/14

Y1 - 2016/6/14

N2 - Background:Ghrelin, a 28-amino acid peptide predominantly produced by the stomach, exerts powerful renal protective effects by increasing levels of insulin-like growth factor-1 (IGF-1). The aim of this study was to evaluate the effects of ghrelin on the incidence of renal dysfunction in patients receiving cisplatin-based chemotherapy.Methods:Forty patients with oesophageal cancer receiving cisplatin-based chemotherapy were assigned to either the ghrelin group (n=20), which received ghrelin (0.5 μg kg -1 h -1) for 5 days, or a placebo group (n=20). The primary endpoint was serum creatinine. Secondary endpoints were serum cystatin C, chemotherapy-related adverse events, changes in serum ghrelin-related hormone levels, correlation between markers of renal injury and hormone concentrations, and effects on the second cycle of chemotherapy.Results:Blood acyl ghrelin, total ghrelin, and IGF-1 concentrations on day 4 were significantly higher in the ghrelin group. The renal dysfunction, serum creatinine and cystatin C levels, dose reduction, and delay in the initiation of the second cycle of chemotherapy were lower in the ghrelin group than in the control group. Serum creatinine levels were significantly correlated with serum IGF-1 levels.Conclusion:Continuous synthetic ghrelin administration during cisplatin-based chemotherapy attenuated renal dysfunction and harmful effects on subsequent chemotherapy, possibly by increasing IGF-1 levels.

AB - Background:Ghrelin, a 28-amino acid peptide predominantly produced by the stomach, exerts powerful renal protective effects by increasing levels of insulin-like growth factor-1 (IGF-1). The aim of this study was to evaluate the effects of ghrelin on the incidence of renal dysfunction in patients receiving cisplatin-based chemotherapy.Methods:Forty patients with oesophageal cancer receiving cisplatin-based chemotherapy were assigned to either the ghrelin group (n=20), which received ghrelin (0.5 μg kg -1 h -1) for 5 days, or a placebo group (n=20). The primary endpoint was serum creatinine. Secondary endpoints were serum cystatin C, chemotherapy-related adverse events, changes in serum ghrelin-related hormone levels, correlation between markers of renal injury and hormone concentrations, and effects on the second cycle of chemotherapy.Results:Blood acyl ghrelin, total ghrelin, and IGF-1 concentrations on day 4 were significantly higher in the ghrelin group. The renal dysfunction, serum creatinine and cystatin C levels, dose reduction, and delay in the initiation of the second cycle of chemotherapy were lower in the ghrelin group than in the control group. Serum creatinine levels were significantly correlated with serum IGF-1 levels.Conclusion:Continuous synthetic ghrelin administration during cisplatin-based chemotherapy attenuated renal dysfunction and harmful effects on subsequent chemotherapy, possibly by increasing IGF-1 levels.

UR - http://www.scopus.com/inward/record.url?scp=84973121363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973121363&partnerID=8YFLogxK

U2 - 10.1038/bjc.2016.160

DO - 10.1038/bjc.2016.160

M3 - Article

C2 - 27253174

AN - SCOPUS:84973121363

VL - 114

SP - 1318

EP - 1325

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 12

ER -